NASDAQ:VCEL Vericel (VCEL) Stock Price, News & Analysis → SHOCKING Crypto Leak… (From Crypto 101 Media) (Ad) Free VCEL Stock Alerts $46.42 +1.04 (+2.29%) (As of 04/23/2024 ET) Add Compare Share Share Today's Range$45.43▼$47.1450-Day Range$43.74▼$52.9052-Week Range$29.24▼$53.05Volume362,327 shsAverage Volume549,232 shsMarket Capitalization$2.25 billionP/E RatioN/ADividend YieldN/APrice Target$46.40 Stock AnalysisStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial MediaStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial Media Get Vericel alerts: Email Address Vericel MarketRank™ Stock AnalysisAnalyst RatingBuy3.00 Rating ScoreUpside/Downside0.0% Downside$46.40 Price TargetShort InterestBearish9.07% of Shares Sold ShortDividend StrengthN/ASustainabilityN/ANews Sentiment0.87Based on 8 Articles This WeekInsider TradingSelling Shares$2.56 M Sold Last QuarterProj. Earnings Growth455.56%From $0.09 to $0.50 Per ShareSee Full Details Hide Full Details Overall MarketRank™New Rank-Based ScoringMarketRank™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.0.58 out of 5 starsMedical Sector853rd out of 910 stocksBiological Products, Except Diagnostic Industry147th out of 153 stocks 1.5 Analyst's Opinion Consensus RatingVericel has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 6 buy ratings, no hold ratings, and no sell ratings.Amount of Analyst CoverageVericel has only been the subject of 2 research reports in the past 90 days. Previous Next 1.0 Short Interest Percentage of Shares Shorted9.07% of the outstanding shares of Vericel have been sold short.Short Interest Ratio / Days to CoverVericel has a short interest ratio ("days to cover") of 8.2.Change versus previous monthShort interest in Vericel has recently increased by 85.23%, indicating that investor sentiment is decreasing significantly. Previous Next 0.0 Dividend Strength Dividend YieldVericel does not currently pay a dividend.Dividend GrowthVericel does not have a long track record of dividend growth. Previous Next N/A Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreThere is no current Upright™ data available for VCEL. Previous Next 2.7 News and Social Media Coverage News SentimentVericel has a news sentiment score of 0.87. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.45 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 8 news articles for Vericel this week, compared to 3 articles on an average week.Search InterestOnly 1 people have searched for VCEL on MarketBeat in the last 30 days. This is a decrease of -67% compared to the previous 30 days.MarketBeat FollowsOnly 1 people have added Vericel to their MarketBeat watchlist in the last 30 days. This is a decrease of -67% compared to the previous 30 days. Previous Next 0.8 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Vericel insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $2,561,506.00 in company stock.Percentage Held by InsidersOnly 7.20% of the stock of Vericel is held by insiders. Previous Next 1.9 Earnings and Valuation Earnings GrowthEarnings for Vericel are expected to grow by 455.56% in the coming year, from $0.09 to $0.50 per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Vericel is -515.72, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Vericel is -515.72, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioVericel has a P/B Ratio of 9.81. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities. Previous Next See Top Rated MarketRank™ Stocks Here Ad Crypto 101 MediaSHOCKING Crypto Leak…A shocking leak has revealed tech giant Microsoft's plans to add crypto support to future products. If the plans in these leaked internal documents pan out, we could see prices skyrocket for Bitcoin, Ethereum, XRP and MORE… The coupling of gaming and cryptocurrency could absolutely transform digital finance as we know it in 2024. Claim your free seat by clicking here now. About Vericel Stock (NASDAQ:VCEL)Vericel Corporation, a commercial-stage biopharmaceutical company, engages in the research, development, manufacture, and distribution of cellular therapies for sports medicine and severe burn care markets in North America. The company markets autologous cell therapy products comprising MACI, an autologous cultured chondrocytes on porcine collagen membrane for the repair of symptomatic, and single or multiple full-thickness cartilage defects of the knee; Epicel, a permanent skin replacement humanitarian use device for the treatment of adult and pediatric patients with deep-dermal or full-thickness burns; and NexoBrid, a biological orphan product for eschar removal in adults with deep partial-thickness and/or full-thickness thermal burns. The company was formerly known as Aastrom Biosciences, Inc. Vericel Corporation was incorporated in 1989 and is headquartered in Cambridge, Massachusetts.Read More VCEL Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart VCEL Stock News HeadlinesApril 21, 2024 | insidertrades.comDominick Colangelo Sells 17,500 Shares of Vericel Co. (NASDAQ:VCEL) StockApril 20, 2024 | insidertrades.comVericel Co. (NASDAQ:VCEL) CEO Sells $780,325.00 in StockApril 23, 2024 | True Market Insiders (Ad)Exposed: 10 CENT Crypto to Explode April 20th?Former Wall Street Insider and Professional Money Manager Reveals 4 Cryptos BETTER Than BitcoinMarch 30, 2024 | insidertrades.comVericel Co. (NASDAQ:VCEL) Director Robert L. Md Zerbe Sells 3,278 SharesApril 21, 2024 | nz.finance.yahoo.comVericel Corporation (VCEL) stock historical prices & data – Yahoo FinanceApril 17, 2024 | money.usnews.comVericel CorpApril 13, 2024 | finance.yahoo.comVericel Corporation (NASDAQ:VCEL) On The Verge Of Breaking EvenApril 7, 2024 | nasdaq.comCommit To Buy Vericel At $25, Earn 9% Annualized Using OptionsApril 23, 2024 | True Market Insiders (Ad)Exposed: 10 CENT Crypto to Explode April 20th?Former Wall Street Insider and Professional Money Manager Reveals 4 Cryptos BETTER Than BitcoinMarch 27, 2024 | markets.businessinsider.comAnalyst Scoreboard: 5 Ratings For VericelMarch 3, 2024 | ca.finance.yahoo.comVCEL Oct 2024 50.000 callMarch 3, 2024 | finance.yahoo.comUS$52.07 - That's What Analysts Think Vericel Corporation (NASDAQ:VCEL) Is Worth After These ResultsMarch 2, 2024 | seekingalpha.comVericel Corporation (VCEL) Q4 2023 Earnings Call TranscriptMarch 2, 2024 | finance.yahoo.comVericel Full Year 2023 Earnings: EPS Beats ExpectationsMarch 1, 2024 | markets.businessinsider.comBuy Rating Affirmed for Vericel on Strong Financials and Growth ProspectsMarch 1, 2024 | markets.businessinsider.comA Closer Look at 4 Analyst Recommendations For VericelMarch 1, 2024 | finance.yahoo.comVericel Corporation (NASDAQ:VCEL) Q4 2023 Earnings Call TranscriptMarch 1, 2024 | finance.yahoo.comVericel Corporation (NASDAQ:VCEL) Shares Could Be 48% Below Their Intrinsic Value EstimateFebruary 29, 2024 | finanznachrichten.deVericel Corporation: Vericel Reports Fourth Quarter and Full-Year 2023 Financial Results and Provides Full-Year 2024 Financial GuidanceFebruary 29, 2024 | msn.comVericel GAAP EPS of $0.26 beats by $0.09, revenue of $65M beats by $1.05MFebruary 29, 2024 | finance.yahoo.comVericel Corp (VCEL) Reports Robust Revenue and EBITDA Growth in Q4 and Full-Year 2023February 29, 2024 | seekingalpha.comVericel Corporation 2023 Q4 - Results - Earnings Call PresentationFebruary 29, 2024 | globenewswire.comVericel Reports Fourth Quarter and Full-Year 2023 Financial Results and Provides Full-Year 2024 Financial GuidanceFebruary 27, 2024 | globenewswire.comVericel to Present at the TD Cowen 44th Annual Health Care Conference on Tuesday, March 5, 2024February 26, 2024 | investorplace.com3 Top Pharma Stocks for Investors Betting on a Biotech BoomFebruary 23, 2024 | finance.yahoo.comVericel Corporation (VCEL)February 21, 2024 | finance.yahoo.comCRSP Mar 2024 79.000 putSee More Headlines Receive VCEL Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Vericel and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings2/29/2024Today4/23/2024Next Earnings (Estimated)5/08/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Biological products, except diagnostic Sub-IndustryN/A Current SymbolNASDAQ:VCEL CUSIPN/A CIK887359 Webwww.vcel.com Phone(617) 588-5555Fax617-588-5554Employees314Year Founded1989Price Target and Rating Average Stock Price Target$46.40 High Stock Price Target$54.00 Low Stock Price Target$39.00 Potential Upside/Downside0.0%Consensus RatingBuy Rating Score (0-4)3.00 Research Coverage6 Analysts Profitability EPS (Most Recent Fiscal Year)($0.09) Trailing P/E RatioN/A Forward P/E Ratio515.67 P/E GrowthN/ANet Income$-3,180,000.00 Net Margins-1.61% Pretax Margin-1.20% Return on Equity-1.55% Return on Assets-1.02% Debt Debt-to-Equity RatioN/A Current Ratio4.49 Quick Ratio4.21 Sales & Book Value Annual Sales$197.52 million Price / Sales11.37 Cash Flow$0.02 per share Price / Cash Flow2,482.13 Book Value$4.73 per share Price / Book9.81Miscellaneous Outstanding Shares48,380,000Free Float44,897,000Market Cap$2.25 billion OptionableOptionable Beta1.71 Social Links 7 AI Stocks to Invest In: An Introduction to AI Investing For Self-Directed InvestorsAs the AI market heats up, investors who have a vision for artificial intelligence have the potential to see real returns. Learn about the industry as a whole as well as seven companies that are getting work done with the power of AI.Get This Free Report Key ExecutivesMr. Dominick C. Colangelo Esq. (Age 60)CEO, President & Director Comp: $1.54MMr. Joseph Anthony Mara Jr. (Age 48)CFO & Treasurer Comp: $750.61kMr. Michael Halpin (Age 63)Chief Operating Officer Comp: $796.91kMr. Sean C. Flynn (Age 50)Senior VP, General Counsel & Secretary Comp: $657.01kDr. Jonathan M. Hopper FRCSEd. (Age 62)M.B. Ch.B., Chief Medical Officer Comp: $672.16kMr. Jonathan D. SiegalPrincipal Accounting Officer, VP & Corporate ControllerMr. Eric BurnsVice President of Finance & Investor RelationsMr. Patrick J. FowlerSenior Vice President of Corporate Development & StrategyMr. Patrick HelfrichVice President of Marketing & Commercial StrategyMs. Heidi HassenSenior Vice President of Human ResourcesMore ExecutivesKey CompetitorsDenali TherapeuticsNASDAQ:DNLICG OncologyNASDAQ:CGONBeam TherapeuticsNASDAQ:BEAMKymera TherapeuticsNASDAQ:KYMRGinkgo BioworksNYSE:DNAView All CompetitorsInsiders & InstitutionsLouisiana State Employees Retirement SystemSold 300 shares on 4/23/2024Ownership: 0.049%KLR Investment Advisors LLCBought 5,519 shares on 4/23/2024Ownership: 0.011%Arcadia Investment Management Corp MIBought 515 shares on 4/23/2024Ownership: 0.001%PFG Investments LLCBought 6,450 shares on 4/22/2024Ownership: 0.013%State of Alaska Department of RevenueSold 287 shares on 4/19/2024Ownership: 0.060%View All Insider TransactionsView All Institutional Transactions VCEL Stock Analysis - Frequently Asked Questions Should I buy or sell Vericel stock right now? 6 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Vericel in the last twelve months. There are currently 6 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "buy" VCEL shares. View VCEL analyst ratings or view top-rated stocks. What is Vericel's stock price target for 2024? 6 equities research analysts have issued 12 month price objectives for Vericel's stock. Their VCEL share price targets range from $39.00 to $54.00. On average, they predict the company's share price to reach $46.40 in the next twelve months. This suggests that the stock has a possible downside of 0.0%. View analysts price targets for VCEL or view top-rated stocks among Wall Street analysts. How have VCEL shares performed in 2024? Vericel's stock was trading at $35.61 at the start of the year. Since then, VCEL stock has increased by 30.4% and is now trading at $46.42. View the best growth stocks for 2024 here. Are investors shorting Vericel? Vericel saw a increase in short interest in March. As of March 31st, there was short interest totaling 4,390,000 shares, an increase of 85.2% from the March 15th total of 2,370,000 shares. Based on an average daily volume of 536,800 shares, the days-to-cover ratio is currently 8.2 days. View Vericel's Short Interest. When is Vericel's next earnings date? The company is scheduled to release its next quarterly earnings announcement on Wednesday, May 8th 2024. View our VCEL earnings forecast. How were Vericel's earnings last quarter? Vericel Co. (NASDAQ:VCEL) released its quarterly earnings data on Thursday, February, 29th. The biotechnology company reported $0.26 EPS for the quarter, beating analysts' consensus estimates of $0.18 by $0.08. The biotechnology company earned $65 million during the quarter, compared to analysts' expectations of $64.28 million. Vericel had a negative net margin of 1.61% and a negative trailing twelve-month return on equity of 1.55%. The firm's quarterly revenue was up 23.3% compared to the same quarter last year. During the same quarter in the prior year, the firm earned $0.12 earnings per share. What ETFs hold Vericel's stock? ETFs with the largest weight of Vericel (NASDAQ:VCEL) stock in their portfolio include Invesco Biotechnology & Genome ETF (PBE), Invesco S&P SmallCap Health Care ETF (PSCH), WisdomTree BioRevolution Fund (WDNA), ALPS Medical Breakthroughs ETF (SBIO), Invesco Dorsey Wright Healthcare Momentum ETF (PTH), SPDR S&P Biotech ETF (XBI), Invesco S&P SmallCap 600 Pure Growth ETF (RZG) and Syntax Stratified SmallCap ETF (SSLY). What guidance has Vericel issued on next quarter's earnings? Vericel updated its FY 2024 earnings guidance on Thursday, February, 29th. The company provided earnings per share guidance of for the period. The company issued revenue guidance of $237.0 million-$241.0 million, compared to the consensus revenue estimate of $240.8 million. What is Nick Colangelo's approval rating as Vericel's CEO? 6 employees have rated Vericel Chief Executive Officer Nick Colangelo on Glassdoor.com. Nick Colangelo has an approval rating of 49% among the company's employees. This puts Nick Colangelo in the bottom 25% of approval ratings compared to other CEOs of publicly-traded companies. What other stocks do shareholders of Vericel own? Based on aggregate information from My MarketBeat watchlists, some companies that other Vericel investors own include Exelixis (EXEL), Novavax (NVAX), Hello Group (MOMO), Dynavax Technologies (DVAX), Synergy Pharmaceuticals (SGYP), Sorrento Therapeutics (SRNE), TG Therapeutics (TGTX), Verastem (VSTM), Amarin (AMRN) and NVIDIA (NVDA). Who are Vericel's major shareholders? Vericel's stock is owned by a variety of institutional and retail investors. Top institutional shareholders include Congress Asset Management Co. MA (1.73%), Allspring Global Investments Holdings LLC (0.82%), Congress Wealth Management LLC DE (0.22%), State of Alaska Department of Revenue (0.06%), Los Angeles Capital Management LLC (0.06%) and Louisiana State Employees Retirement System (0.05%). Insiders that own company stock include Dominick Colangelo, Jonathan Mark Hopper, Jonathan Siegal, Michael Halpin, Paul K Wotton, Robert L Md Zerbe, Sean C Flynn and Steven C Gilman. View institutional ownership trends. How do I buy shares of Vericel? Shares of VCEL stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. This page (NASDAQ:VCEL) was last updated on 4/23/2024 by MarketBeat.com Staff From Our PartnersThe A.I. story nobody is telling you (Read ASAP)TradeSmithSHOCKING Crypto Leak…Crypto 101 MediaDid You Get Your Free Bitcoin Yet?Crypto Swap Profitstop AI stock (it’s not MSFT, GOOGL, AMZN or AAPL)Traders AgencyDon’t Miss Out on the AI Gold Rush That’s Just Getting StartedBanyan Hill PublishingUrgent Alert: Biden's IRS Targeting Your Money – Act Fast to Protect It!American AlternativeHow to camouflage a factory of 53,000 workersStansberry ResearchMan Who Predicted 2008: “This Will be Worse.”Altimetry Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Vericel Co. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
